Drugs / CM369
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05690581 | Feb 2023 → Oct 2025 overdue | — | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-06-02 | Beijing InnoCare Pharma Tech Co., Ltd. | Results 诺诚健华在2025年美国ASCO年会发布一系列创新管线最新数据 innocarepharma.com ↗
结果显示，33.3%的患者实现部分缓解（PR），58.3%的患者评估为疾病稳定（SD），伴随皮肤病变减少，6 个月无疾病进展率（PFS） 为 82.5%，中位PFS为11.4个月。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-06-02 | Beijing InnoCare Pharma Tech Co., Ltd. | 诺诚健华在2025年美国ASCO年会发布一系列创新管线最新数据 innocarepharma.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CM369 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05690581 ↗ |